Disease burden of herpes zoster in Korea
Disease burden of herpes zoster in Korea
复制标题
DOI：
10.1016/j.jcv.2010.01.003
复制
发表时间：
2010-04-01
影响因子：
8.8
通讯作者：
Cheong, Hee Jin
中科院分区：
文献类型：
--
作者：
Choi, Won Suk;Noh, Ji Yun;Cheong, Hee Jin
背景：带状疱疹的发生可大大降低生活质量，造成较高的疾病负担。虽然韩国被认为是带状疱疹疾病负担较高的国家，但没有对此进行分析的研究。目的：我们进行了这项研究，以调查带状疱疹的疾病负担在韩国人口作为一个整体。研究设计：我们使用韩国健康保险审查与评估服务的数据库，分析2003 - 2007年期间以带状疱疹为主要诊断的患者的数据。我们调查了年患病率、临床诊断率、住院率和医疗服务使用模式。带状疱疹的社会经济负担通过转换成成本来计算。结果：2003 ~ 2007年5年间，因带状疱疹就诊和住院率分别为7.93 ~ 12.54 / 1000人和0.22 ~ 0.32 / 1000人。按年龄划分的患病率在50岁后急剧上升，在70岁时达到高峰。带状疱疹的社会经济总成本为每年759 - 1.438亿美元，每年增加14-20%。结论：韩国带状疱疹造成了沉重的社会经济负担，需要制定适当的政策来减轻这一负担。还需要进一步的研究来评估带状疱疹疫苗在韩国人口中的安全性、有效性和成本效益。(C) 2010 Elsevier B.V.版权所有
Background: The occurrence of herpes zoster can deteriorate the quality of life considerably, resulting in high disease burden. While Korea is assumed to have high disease burden of herpes zoster, there has been no researches analyzing this.Objectives: We performed this study to investigate the disease burden of herpes zoster in the Korean population as a whole.Study design: We used the database of the Health Insurance Review & Assessment Service of Korea and analyzed the data of patients who had herpes zoster as a principal diagnosis during the period from 2003 to 2007. We investigated the annual prevalence, rate of clinical visits, rate of hospitalization, and the pattern of medical services use. The socioeconomic burden of herpes zoster was calculated by a conversion into cost.Results: Rates of clinic visits and hospitalizations due to herpes zoster during the 5-year period from 2003 to 2007 were 7.93-12.54 per 1000 population and 0.22-0.32 per 1000 population, respectively. Prevalence rates according to age increased sharply after 50 years and reached a peak at 70 years. The total socioeconomic cost of herpes zoster was $75.9-143.8 million per year, increasing every year by 14-20%.Conclusions: There is a heavy socioeconomic burden due to herpes zoster in Korea and indicate that appropriate policies need to be established to reduce this burden. Additional researches are also necessary to assess the safety, efficacy and cost-effectiveness of a herpes zoster vaccine in the Korean population. (C) 2010 Elsevier B.V. All rights reserved.